New complement-targeting treatments are changing the therapeutic landscape for C3 glomerulopathy (C3G), primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), and IgA nephropathy (IgAN), raising important questions about how to use them in clinical practice. To explore these questions, the ISN convened the
Receive updates from International Society of Nephrology for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from International Society of Nephrology. Unsubscribe at any time.
Site title: International Society of Nephrology